Capmatinib successfully overcomes tepotinib‐induced intolerable peripheral edema

Abstract In May 2020 and February 2021, capmatinib and tepotinib, respectively were approved by the Food and Drug Administration (FDA) for the treatment of metastatic non‐small cell lung carcinoma harboring mesenchymal‐epithelial transition (MET) exon 14 skipping alterations. Herein, we present a ca...

Full description

Bibliographic Details
Published in:Thoracic Cancer
Main Authors: Kei Kunimasa, Takahisa Kawamura, Motohiro Tamiya, Takako Inoue, Hanako Kuhara, Kazumi Nishino, Toru Kumagai
Format: Article
Language:English
Published: Wiley 2021-12-01
Subjects:
capmatinib
MET ex.14 skipping
peripheral edema
tepotinib
Online Access:https://doi.org/10.1111/1759-7714.14205
Description
Summary:Abstract In May 2020 and February 2021, capmatinib and tepotinib, respectively were approved by the Food and Drug Administration (FDA) for the treatment of metastatic non‐small cell lung carcinoma harboring mesenchymal‐epithelial transition (MET) exon 14 skipping alterations. Herein, we present a case of intolerable peripheral edema caused by tepotinib, in which MET inhibitor could be continued by switching to capmatinib. Peripheral edema has been identified as one of the most common adverse events in capmatinib and tepotinib; however, there is no unified management for this adverse event. This is the first report that two MET inhibitors have different effects on the development of peripheral edema, and that the MET inhibitors can be continued by switching these drugs.
ISSN:1759-7706
1759-7714

Similar Items